AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03992027 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Participants receive usual care for 3 months followed by CF-CBT. CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
Study NCT06461936 — intervention group
Intervention type: DRUG
Intervention: Sintilimab
Description: Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
Study NCT06461936 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: Lenvatinib is initiated orally 2-4 weeks postoperatively for about 6 months.
Study NCT00994461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 100mg tablet twice a day with meal for 2 weeks
Study NCT02520063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
Study NCT02520063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
Study NCT02520063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
Study NCT04431596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm cooling
Description: forearm immersion will be performed for active cooling assessment.
Study NCT04431596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mist-fan cooling
Description: A mist-fan will be placed in front of the participant for active cooling.
Study NCT02031887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formula with synbiotics
Study NCT02031887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: formula without synbiotics
Study NCT03206320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Topical
Description: Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
Study NCT03206320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Topical
Description: Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
Study NCT02811861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Study NCT02811861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02811861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02811861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Study NCT02172755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
Study NCT00686166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Chemotherapy cycle 1: Cetuximab, 400 mg/m\^2, IV, Day 1; Cetuximab, 250 mg/m\^2, IV, Days 8,15,22,29~Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m\^2, IV, Days 50,57,64,71,78
Study NCT00686166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Chemotherapy Cycle 1: Capecitabine, 1650 mg/m\^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m\^1, PO, Monday-Friday (Day 50-84)
Study NCT00686166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m\^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m\^2, IV, Days 50,57,71,78
Study NCT00686166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic surgical procedure
Description: Surgical resection
Study NCT00686166 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: IMRT (intensity-modulated radiation therapy)
Study NCT03474042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737
Description: GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
Study NCT03474042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
Study NCT04263883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Study or Experimental Group
Description: 3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
Study NCT04263883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study or Experimental Group
Description: 3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
Study NCT00433498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Should be given according to local practice but suggested doses and schedules are provided in the protocol.
Study NCT00433498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Should be given according to local practice but suggested doses and schedules are provided in the protocol.
Study NCT00433498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: Should be given according to local practice but suggested doses and schedules are provided in the protocol.
Study NCT00433498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Should be given according to local practice but suggested doses and schedules are provided in the protocol.
Study NCT00433498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etoposide phosphate
Description: Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
Study NCT00433498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
Study NCT00433498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin sodium
Description: 40mg daily oral tablet taken for a maximum of 2 years
Study NCT03036124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg or 5 mg tablets given once daily, per oral use.
Study NCT03036124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching dapagliflozin 10 mg or 5 mg.
Study NCT00508066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine 0.25 - 0.5% @ 4ml/hr for 72 hours
Study NCT00508066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline, 4ml/hour for 72 hours.
Study NCT05113628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: methylene blue identification
Description: After ligation of the middle thyroid vein and the upper pole of the thyroid, the thyroid lobe was retracted medially and diluted methylene blue (0.5 ml methylene blue 2% was diluted by 5ml normal saline) was sprayed over the lower thyroid pole and the perilobar area. This area contains structures including recurrent laryngeal nerve, parathyroid glands, and inferior thyroid vessels which were observed After spraying.~The vocal cord mobility was assessed intraoperatively by the anesthesiologist at time of extubation. The serum calcium was measured on the 2nd postoperative day. There was no routine use of postoperative calcium supplementation. Hypocalcemia was defined when the serum calcium level was less than 8 mg/dl.
Study NCT00994461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxoprofen
Description: Loxoprofen 60mg tablet three times a day with meal for 2 weeks
Study NCT00994461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet three times a day with meal for 2 weeks
Study NCT03055312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC
Description: Conventional chemotherapy(choose a):~TX:(Docetaxel 75mg/m2 iv day1 and Capecitabine 950mg/m2 po twice daily days 1-14)every 3 weeks.~GT:(Paclitaxel 175mg/m2 iv day1 and Gemcitabine 1250mg/m2 iv days 1 \& days 8)every 3 weeks.~GC:(Gemcitabine 1000mg/m2 on days 1 \& days 8 and Carboplatin by Area Under Curve (AUC) 2 iv on days 1 \& days 8) every 3 weeks
Study NCT03055312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg
Description: Bicalutamide 150mg/day,every 28 days
Study NCT03990883 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Princess Filler Lidocaine
Description: correction of nasolabial folds
Study NCT03422250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: 10 daily 25-minutes tDCS sessions over two weeks.
Study NCT02173665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - Powder in bottle (PIB)
Study NCT02173665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - Tablet
Study NCT02173665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04224077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optimisation of DTI sequences
Description: Optimisation of DTI sequences in the study of lumbar roots by MRI
Study NCT03045666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: patients who are stable on Macitentan therapy (received in both groups before enrollment) and will exercise at a pulmonary rehabilitation program twice a week for 12 weeks
Study NCT03816904 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples before the introduction of chemotherapy
Study NCT05517317 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous BMMC transplantation
Description: One administration of autologous bone marrow mononuclear cells via the hepatic artery
Study NCT01483274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
Study NCT01483274 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine
Description: Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
Study NCT04400851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients were enrolled by the design of phase I study standard. Sintilimab was divided into three dosage levels: 1 mg / kg, 3 mg / kg, and 10 mg / kg. The first level of sintilimab was followed by dose escalation
Study NCT01659606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Conditioning: alemtuzumab 0.2 mg/kg/dose IV/SC x 5 doses
Study NCT01659606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: fludarabine 30 mg/m2/dose IV x 6 doses
Study NCT01659606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporins
Study NCT01659606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT01659606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT02329171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.
Study NCT02329171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ
Description: Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
Study NCT00237458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Dosage: Lacosamide up to 400 mg/day;~Dosage form: Film-coated tablets;~Dosage Frequency and Duration: Two times per day; 9.5 years
Study NCT03073031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tablet: Samsung Galaxy Tab A
Study NCT04707521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3M tape ship-shaped combined with strap fixing method
Description: During fixation, the endotracheal intubation and dental pad were located in the center of the mouth, and one end of one piece of medical cloth adhesive was pasted on the patient's cheek near the side. When it reached one side of the mouth, the endotracheal intubation and dental pad were wound around twice, and then the other side of the adhesive tape was pasted on the cheek opposite the side from the other side of the mouth,The other is fixed in reverse with the same sticking method, and the two pieces of adhesive tape are finally crossed and fixed at the corners of the mouth.Finally, fasten it with a lacing
Study NCT01725022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Care
Description: This is the interventional arm where patients receive the transplant care in their homes.
Study NCT00800995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SOD
Study NCT00800995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT03831113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnitude Group
Description: Dose reductions will alternate between 1mg or 2 mg weekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
Study NCT03831113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frequency Group
Description: Dose reductions of 2 mg will occur alternate between once weekly to biweekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
Study NCT01925950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orBec
Study NCT01925950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04719780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy for Individuals
Description: Emotionally Focused Therapy for Individuals (EFIT) is formulated as a transdiagnostic treatment to treat depression and anxiety, adapted from the well-studied Emotionally Focused Therapy. EFIT has been formulated as an attachment-based alternative to current cognitive approaches (e.g., Cognitive Behavioural Therapy). The strong evidence for insecure attachment as an underlying factor in psychopathology, especially depression and anxiety, positions this theory well as a foundational principle to support psychotherapy for these conditions.
Study NCT04719780 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help CBT Training
Description: Individuals in the Waitlist Control Group will receive access to MoodGym, a self-help online program that helps teach CBT interventions. This access will last 15 weeks and is self-driven, meaning participants proceed through the program at their own pace.
Study NCT02316600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart insole
Description: smart insole to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
Study NCT01202578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tympanostomy tube
Description: tympanostomy tube delivery system
Study NCT02541513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliparidone
Description: All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
Study NCT01891916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extensively hydrolyzed casein formula + LGG
Description: Extensively hydrolyzed formula containing Lactobacillus GG
Study NCT00066248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyproheptadine hydrochloride
Description: Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
Study NCT00066248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate
Description: Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
Study NCT04063189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen
Description: Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23
Study NCT02231827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Subjects, barefoot and standing upright and motionless on a force plate, were instructed to walk for 10 m following a beep delivered by the experimenter. Two experimental conditions were tested: (i) the 'natural' gait condition where subjects walked normally and (ii) the 'fast' gait condition where subjects walked as fast as they could, taking large steps. Each subject performed 10 trials in each condition.
Study NCT03318523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT03318523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: Administered as specified in the treatment arm.
Study NCT00501176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic and metalic stent inserion
Description: Patient randomizes to metal or plastic insertion prior to Whipple procedure
Study NCT00478348 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prosthetic repair of abdominal incisional hernia
Description: Rives-Stoppa repair of incisional hernia
Study NCT01991626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: micronutrient powder
Study NCT01991626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: micronutrient powder (containing FeSO4), phytase
Study NCT01991626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron pyrophosphate (FePP)
Study NCT01991626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron sulphate
Study NCT00591890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indibulin
Description: dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
Study NCT05263752 — intervention group
Intervention type: DEVICE
Intervention: ERCP with NvisionVLE® Imaging Low Profile System
Description: Endoscopic Retrograde Cholangio-Pancreatography (ERCP) with NvisionVLE® Imaging Low Profile System
Study NCT04326270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal interface
Description: Randomized to initial interface of nCPAP prongs or infant cannula